What is the main purpose of this 8-K filing?

The main purpose of this 8-K filing is to publicly disclose Amgen's "Amgen Update Regarding COVID-19 for Media" to comply with Regulation FD, ensuring that information shared with the media and public is made available to all investors simultaneously.

Where can I find the details of Amgen's COVID-19 update?

The full details of Amgen's COVID-19 update are provided in Exhibit 99.1, which is attached to this 8-K filing and was also posted on Amgen's website.

Does this filing contain any new financial results or business operations updates?

No, this 8-K filing does not contain new financial results or updates on specific business operations. It is solely a Regulation FD disclosure regarding Amgen's perspective on COVID-19.

Are the statements in this filing legally binding or considered 'filed'?

The information disclosed under Item 7.01 (Regulation FD Disclosure) and in Exhibit 99.1 is generally not deemed 'filed' for the purposes of Section 18 of the Securities Exchange Act of 1934, nor is it incorporated by reference into other filings under the Securities Act of 1933 or the Exchange Act, unless expressly stated otherwise.

AMGN 8-K: Regulation FD

Summary

Amgen Inc. (AMGN) filed an 8-K on March 31, 2020, to disclose an update regarding its perspective on COVID-19, posted on its website. This filing is primarily a Regulation FD disclosure, providing information to the public concurrently with its release on Amgen's official channels. The content of this update, attached as Exhibit 99.1, is not considered 'filed' for certain legal purposes but is made available for investor awareness. Investors should refer to the exhibit for the specific details of Amgen's COVID-19 perspective.

Key Highlights

1Amgen released an "Amgen Update Regarding COVID-19 for Media" on March 31, 2020.
2This information was posted on Amgen's official website.
3The filing is categorized under Item 7.01 (Regulation FD Disclosure) and Item 9.01 (Financial Statements and Exhibits).
4Exhibit 99.1 contains the full text of the COVID-19 update.
5The disclosure is intended to ensure widespread public dissemination of information.
6Information provided under Regulation FD disclosure is generally not considered 'filed' for the purposes of Section 18 of the Exchange Act.
7The filing includes the standard Cover Page Interactive File as Exhibit 104.

AMGEN INC 8-K Report, Regulation FD Disclosure (Mar 31, 2020)

Summary

Key Highlights

Frequently Asked Questions